アルテプラーゼ
参考資料

1 2  “Alteplase Use During Pregnancy”. Drugs.com. 27 August 2020時点のオリジナルよりアーカイブ。12 November 2019閲覧。
1 2 3 4  “Activase- alteplase kit”. DailyMed (5 December 2018). 11 January 2017時点のオリジナルよりアーカイブ。4 January 2020閲覧。
1 2 3  “Cathflo Activase- alteplase injection, powder, lyophilized, for solution”. DailyMed (6 September 2019). 29 January 2021時点のオリジナルよりアーカイブ。14 November 2020閲覧。
↑  “Actilyse”. European Medicines Agency. 17 November 2020時点のオリジナルよりアーカイブ。14 November 2020閲覧。
1 2 3 4 5  “Alteplase Monograph for Professionals”. Drugs.com. 27 August 2020時点のオリジナルよりアーカイブ。11 November 2019閲覧。
1 2 3  “Management of occlusion and thrombosis associated with long-term indwelling central venous catheters”. Lancet 374 (9684):  159–69. (July 2009). doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814365/.
1 2 3 4 5 6 7 8  “Tissue Plasminogen Activator”. StatPearls. Treasure Island (FL): StatPearls Publishing. (April 2020). PMID 29939694.  オリジナルの29 January 2021時点におけるアーカイブ。. https://web.archive.org/web/20210129070457/https://www.ncbi.nlm.nih.gov/books/NBK507917/ 2020年11月10日閲覧。
1 2 3 4 5  “アクチバシン注600万／アクチバシン注1200万／アクチバシン注2400万 添付文書”. www.info.pmda.go.jp. 2021年12月20日閲覧。
1 2 3 4 5  “グルトパ注600万／グルトパ注1200万／グルトパ注2400万 添付文書”. www.info.pmda.go.jp. 2021年12月20日閲覧。
1 2 3 4  “2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines”. Circulation 127 (4):  e362-425. (January 2013). doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304.
1 2 3 4 5  “Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 50 (12):  e344–e418. (December 2019). doi:10.1161/STR.0000000000000211. PMID 31662037.
↑  “2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 49 (3):  e46–e110. (March 2018). doi:10.1161/STR.0000000000000158. PMID 29367334.
1 2 3 4  “Alteplase”. StatPearls. Treasure Island (FL): StatPearls Publishing. (2020). PMID 29763152.  オリジナルの29 January 2021時点におけるアーカイブ。. http://www.ncbi.nlm.nih.gov/books/NBK499977/ 2020年10月30日閲覧。
↑   TPA Therapy. Treasure Island: StatPearls. (2020)
1 2  Solomon, Caren G., ed (July 2020). “Acute Ischemic Stroke”. The New England Journal of Medicine 383 (3):  252–260. doi:10.1056/NEJMcp1917030. PMID 32668115.
↑  “Mechanical Thrombectomy Outcomes With and Without Intravenous Thrombolysis in Stroke Patients: A Meta-Analysis”. Stroke 48 (9):  2450–2456. (September 2017). doi:10.1161/STROKEAHA.117.017320. PMID 28747462.
1 2 3 4  “Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association”. Stroke 47 (2):  581–641. (February 2016). doi:10.1161/STR.0000000000000086. PMID 26696642.
↑  “Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review”. Journal of Stroke and Cerebrovascular Diseases 28 (10):  104290. (October 2019). doi:10.1016/j.jstrokecerebrovasdis.2019.07.006. PMID 31371140.
↑  “Pediatric Thrombolysis: A Practical Approach”. Frontiers in Pediatrics 5:  260. (December 2017). doi:10.3389/fped.2017.00260. PMC 5723643. PMID 29270396. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723643/.
↑  “Thrombolysis in pediatric stroke study”. Stroke 46 (3):  880–5. (March 2015). doi:10.1161/STROKEAHA.114.008210. PMC 4342311. PMID 25613306. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342311/.
↑  “Recombinant tissue plasminogen activators (rtPA): a review”. Clinical Pharmacology and Therapeutics 97 (3):  274–85. (2015-03). doi:10.1002/cpt.33. PMID 25670034.
1 2  Marchand DK, Farrah K (9 July 2019). Thrombolytics for Acute Myocardial Infarction in a Pre-Hospital Setting: A Review of Comparative Safety and Guidelines (PDF). CADT (Report). 2019年10月20日時点のオリジナルよりアーカイブ (PDF)。2020年11月12日閲覧。
↑  “Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis”. Lancet 390 (10096):  747–759. (August 2017). doi:10.1016/s0140-6736(17)31441-1. PMID 28831992.
1 2 3 4  “Update on Thrombolytic Therapy in Acute Pulmonary Thromboembolism”. The Eurasian Journal of Medicine 51 (2):  186–190. (June 2019). doi:10.5152/eurasianjmed.2019.19291. PMC 6592452. PMID 31258361. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592452/.
↑  “Systemic Thrombolysis for Pulmonary Embolism: A Review”. P & T 41 (12):  770–775. (December 2016). PMC 5132419. PMID 27990080. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132419/.
1 2 3  “Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review”. European Heart Journal 35 (12):  758–64. (March 2014). doi:10.1093/eurheartj/ehu029. PMID 24497337.
↑  “Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis”. Thrombosis Research 133 (3):  357–63. (March 2014). doi:10.1016/j.thromres.2013.12.026. PMID 24412030.
↑  “Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials”. Circulation 110 (6):  744–9. (August 2004). doi:10.1161/01.CIR.0000137826.09715.9C. PMID 15262836.
1 2  “Management of PE”. American College of Cardiology (January 2020). 28 November 2020時点のオリジナルよりアーカイブ。2020年10月30日閲覧。
1 2  “Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report”. Chest 149 (2):  315–352. (February 2016). doi:10.1016/j.chest.2015.11.026. PMID 26867832.
1 2 3  “Thrombolytic therapy for central venous catheter occlusion”. Haematologica 97 (5):  641–50. (May 2012). doi:10.3324/haematol.2011.050492. PMC 3342964. PMID 22180420. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342964/.
↑  “Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review”. Pharmacotherapy 31 (10):  1031–40. (October 2011). doi:10.1592/phco.31.10.1031. PMID 21950645.
↑  “HIGHLIGHTS OF PRESCRIBING INFORMATION - ACTIVASE (alteplase) for injection, for intravenous use”. 2021年12月20日閲覧。
↑  “Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS”. Current Cardiology Reports 17 (10):  81. (October 2015). doi:10.1007/s11886-015-0633-5. PMID 26277361.
1 2  “Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials”. Lancet 384 (9958):  1929–35. (November 2014). doi:10.1016/S0140-6736(14)60584-5. PMC 4441266. PMID 25106063. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441266/.
↑  “Activase: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). 27 August 2020時点のオリジナルよりアーカイブ。4 January 2020閲覧。
1 2  “The tissue-type plasminogen activator story”. Arteriosclerosis, Thrombosis, and Vascular Biology 29 (8):  1151–5. (August 2009). doi:10.1161/ATVBAHA.108.179655. PMID 19605778.
↑  “グルトパ注600万／グルトパ注1200万／グルトパ注2400万 インタビューフォーム”. www.info.pmda.go.jp. 2021年12月20日閲覧。
1 2  “Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability”. Stroke 46 (8):  2341–6. (August 2015). doi:10.1161/STROKEAHA.114.007564. PMID 26152294.
↑  “Tissue-type plasminogen activator: a historical perspective and personal account”. Journal of Thrombosis and Haemostasis 2 (4):  541–6. (April 2004). doi:10.1111/j.1538-7933.2004.00645.x. PMID 15102005.
↑   World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. (2019). hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO
↑   Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. (2019). hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO
1 2  “Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature”. Journal of Neurology 268 (8):  2723–2734. (March 2020). doi:10.1007/s00415-020-09803-6. PMID 32206899.
1 2  “Presentation, Evaluation, Management, and Outcomes of Acute Stroke in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis”. Neuroepidemiology 51 (1–2):  104–112. (2018). doi:10.1159/000491442. PMC 6322558. PMID 30025394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322558/.
↑  “Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis”. Trials 17 (1):  473. (September 2016). doi:10.1186/s13063-016-1595-7. PMC 5039798. PMID 27677444. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039798/.
1 2  “Sex differences in IV thrombolysis treatment for acute ischemic stroke: A systematic review and meta-analysis”. Neurology 95 (1):  e11–e22. (July 2020). doi:10.1212/wnl.0000000000009733. PMID 32522796.